Key Metrics of EnerSyn Global Inc.
Revenue$1.2KFY 2023
Operating income—
Net profit−$1.1M▼ 1,051.6% YoY
Shareholders' equity−$3.6M
Market cap$52.3MESYN · $1.76
Competitors10identified
About EnerSyn Global Inc.
Sectors
Company details
- Founded
- 2022
- Listed
- Nasdaq: ESYN (since 2022)
Operational Areas of EnerSyn Global Inc.
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameEnerSyn Global Inc.
TickerESYN
ExchangeNasdaq
CountryUnited States
SEC CIK0001897245
Listed since2022
IndustryOther Pharmaceuticals
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Website—
US market & SEC filings
ESYN · Nasdaq · SEC CIK 0001897245
Last price · 23 Oct 2026
$1.76
−6.63%
Market cap$52.3M
P/E—On FY 2023 diluted EPS
Volume2,037
SectorHealth CareOther Pharmaceuticals
Country · IPOUnited StatesListed 2022
ESYN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of EnerSyn Global Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.